Literature DB >> 1976548

Tumor marker CA 125 level and ovarian volume at different cycle day periods and in postmenopause.

S Granberg1, M Wikland, L G Friberg.   

Abstract

The value of using CA 125 for screening of ovarian carcinoma is still under debate. It is important to be aware of possible physiological variation in serum levels of this antigen. This study aimed at finding out whether there were any differences in CA 125 levels in serum at different cycle day periods of fertile women and postmenopausal women. In 106 women, CA 125 and ovarian volume were measured at different cycle day periods and in postmenopausal women. The highest levels were found in cycle day (CD) 1-9, i.e. 22 units/ml and the lowest in postmenopausal women i.e. 6.7 units/ml. No correlation could be found between the CA 125 levels and ovarian volume as measured by vaginal sonography.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1976548     DOI: 10.1016/0020-7292(90)90588-c

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  3 in total

1.  Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers.

Authors:  Ying Chen; Elizabeth Bancroft; Sue Ashley; Audrey Arden-Jones; Sarah Thomas; Susan Shanley; Sibel Saya; Emma Wakeling; Rosalind Eeles
Journal:  Fam Cancer       Date:  2014-06       Impact factor: 2.375

2.  Clinical and histological profile of surgically managed benign adnexal masses.

Authors:  Vaidyanathan Gowri; Maryam Al Shukri; Maha Al Khaduri; Lovina Machado
Journal:  Oman Med J       Date:  2014-05

3.  Premenopausal early-stage endometrial carcinoma patients with low CA-125 levels and low tumor grade may undergo ovary-saving surgery.

Authors:  Seung-Chul Yoo; Jong-Hyuck Yoon; Woo Young Kim; Suk-Joon Chang; Hee-Jae Joo; Ki-Hong Chang; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2009-09-30       Impact factor: 4.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.